What’s the current market cap for Bio-Techne stock?

Bio-Techne (TECH) has a market cap of $8.8bn as of June 17, 2026.

What is the P/E ratio for Bio-Techne stock?

The price to earnings (P/E) ratio for Bio-Techne (TECH) stock is 80.65 as of June 17, 2026.

Does Bio-Techne stock pay dividends?

Yes, the Bio-Techne (TECH) stock pays dividends to shareholders. As of June 17, 2026, the dividend rate is $0.32 and the yield is 0.57%. Bio-Techne has a payout ratio of 45.47% on a trailing twelve-month basis.

When is the next Bio-Techne dividend payment date?

The next Bio-Techne (TECH) dividend payment date is unconfirmed.

What is the beta indicator for Bio-Techne?

Bio-Techne (TECH) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Bio-Techne stock | $TECH Share Price

13:30

15:10

16:45

18:25

20:00

About Bio-Techne

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Ticker

$TECH

Sector

Health

Primary listing

NASDAQ

Employees

3,100

Headquarters

Minneapolis, United States

Website

www.bio-techne.com

Bio-Techne Metrics

BasicAdvanced

$8.8bn

80.65

$0.69

1.40

$0.32

0.57%

What the Analysts think about Bio-Techne

Analyst ratings (Buy, Hold, Sell) for Bio-Techne stock.

Bulls say / Bears say

Bio-Techne’s board authorized a repurchase of up to $500 million in common stock, highlighting management’s confidence in the company’s cash flow and capital management. (Reuters)

Bio-Techne reported adjusted EPS of $0.56 for the quarter ended March 31, beating analysts’ projection of $0.51 and reflecting strong profitability. (Reuters)

Protein sciences unit sales rose 6% year-over-year to $227.7 million for the quarter, driven by increased demand from major pharmaceutical customers. (Reuters)

Third-quarter revenue of $311.4 million missed analysts' estimates of $317.1 million, as reduced U.S. academic funding lowered demand for Bio-Techne’s products. (Reuters)

Revenue from the Diagnostics and Genomics segment fell 4% to $85.6 million, below the expected $86.58 million, showing continued headwinds in the diagnostics market. (Reuters)

Adjusted EPS of $0.53 was just below consensus estimates of $0.54, indicating margin pressure even as the company tries to control costs. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.

Bio-Techne Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Bio-Techne Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TECH

Capital at risk

Market open

Upcoming events

No upcoming events